TY  - JOUR
AU  - Singh, Jagtar
AU  - Thachil, Thanuja
AU  - Misir, Sema
AU  - Altay, Diler
AU  - Yaman, Serap
AU  - Singh, Gurpreet
AU  - Eapen, Mathew
AU  - McAlinden, Kielan
AU  - Petrović, Nina
AU  - Sohal, Sukhwinder
PY  - 2024
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/13133
AB  - Radiation‑induced normal tissue toxicity is a common acute and chronic outcome of radiotherapy (RT) for prostate cancer (PCa). There are currently no existing pre‑assessments before treatment to predict acute and late RT‑induced toxicity. Novel predictive blood biomarkers in radiation oncology may improve treatment decision‑making and therapeutic monitoring for patients with PCa. A comprehensive systematic search of microRNA (miRNA/miR) profiling studies published in PubMed, Science Direct and Google Scholar was performed. The present systematic review, supported by meta‑analysis, summarises key findings and discusses the results of prospective clinical studies investigating miRNA expression levels and their association with RT‑induced toxicity in PCa. Out of seven clinical studies, six highlighted levels of 10 miRNAs changing in plasma, serum or peripheral blood mononuclear cells during RT. The post‑RT expression levels of miRNA‑132‑5p, miRNA‑1‑3p, miRNA‑410 and miRNA‑221 were increased, and miRNA‑23a‑3p expression was decreased among patients with low‑grade RT‑induced toxicity. Furthermore, in patients with high‑grade RT toxicity, miRNA‑197‑3p, miRNA‑151a‑5p, miRNA‑18b‑5p, miRNA‑99a and miRNA‑21 expression was increased, while miRNA‑132‑5p expression was decreased. The present miRNA meta‑analysis could be the focus of future studies to identify their potential clinical value as PCa biomarkers and therapeutic mediators in RT‑induced toxicity. The variations in miRNA levels post‑RT could be used as predictive biomarkers of RT‑induced toxicity. However, further extensive validation is required to establish the relationship between miRNA expression levels and RT‑induced toxicity in PCa and to confirm their predictive value.
T2  - World Academy of Sciences Journal
T1  - Expression of microRNAs following radiation therapy and association with severity of radiotherapy‑induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta‑analysis
VL  - 6
IS  - 3
DO  - 10.3892/wasj.2024.242
ER  - 

@article{
author = "Singh, Jagtar and Thachil, Thanuja and Misir, Sema and Altay, Diler and Yaman, Serap and Singh, Gurpreet and Eapen, Mathew and McAlinden, Kielan and Petrović, Nina and Sohal, Sukhwinder",
year = "2024",
abstract = "Radiation‑induced normal tissue toxicity is a common acute and chronic outcome of radiotherapy (RT) for prostate cancer (PCa). There are currently no existing pre‑assessments before treatment to predict acute and late RT‑induced toxicity. Novel predictive blood biomarkers in radiation oncology may improve treatment decision‑making and therapeutic monitoring for patients with PCa. A comprehensive systematic search of microRNA (miRNA/miR) profiling studies published in PubMed, Science Direct and Google Scholar was performed. The present systematic review, supported by meta‑analysis, summarises key findings and discusses the results of prospective clinical studies investigating miRNA expression levels and their association with RT‑induced toxicity in PCa. Out of seven clinical studies, six highlighted levels of 10 miRNAs changing in plasma, serum or peripheral blood mononuclear cells during RT. The post‑RT expression levels of miRNA‑132‑5p, miRNA‑1‑3p, miRNA‑410 and miRNA‑221 were increased, and miRNA‑23a‑3p expression was decreased among patients with low‑grade RT‑induced toxicity. Furthermore, in patients with high‑grade RT toxicity, miRNA‑197‑3p, miRNA‑151a‑5p, miRNA‑18b‑5p, miRNA‑99a and miRNA‑21 expression was increased, while miRNA‑132‑5p expression was decreased. The present miRNA meta‑analysis could be the focus of future studies to identify their potential clinical value as PCa biomarkers and therapeutic mediators in RT‑induced toxicity. The variations in miRNA levels post‑RT could be used as predictive biomarkers of RT‑induced toxicity. However, further extensive validation is required to establish the relationship between miRNA expression levels and RT‑induced toxicity in PCa and to confirm their predictive value.",
journal = "World Academy of Sciences Journal",
title = "Expression of microRNAs following radiation therapy and association with severity of radiotherapy‑induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta‑analysis",
volume = "6",
number = "3",
doi = "10.3892/wasj.2024.242"
}

Singh, J., Thachil, T., Misir, S., Altay, D., Yaman, S., Singh, G., Eapen, M., McAlinden, K., Petrović, N.,& Sohal, S.. (2024). Expression of microRNAs following radiation therapy and association with severity of radiotherapy‑induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta‑analysis. in World Academy of Sciences Journal, 6(3).
https://doi.org/10.3892/wasj.2024.242

Singh J, Thachil T, Misir S, Altay D, Yaman S, Singh G, Eapen M, McAlinden K, Petrović N, Sohal S. Expression of microRNAs following radiation therapy and association with severity of radiotherapy‑induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta‑analysis. in World Academy of Sciences Journal. 2024;6(3).
doi:10.3892/wasj.2024.242 .

Singh, Jagtar, Thachil, Thanuja, Misir, Sema, Altay, Diler, Yaman, Serap, Singh, Gurpreet, Eapen, Mathew, McAlinden, Kielan, Petrović, Nina, Sohal, Sukhwinder, "Expression of microRNAs following radiation therapy and association with severity of radiotherapy‑induced toxicity among patients with prostate adenocarcinoma: A systematic review and meta‑analysis" in World Academy of Sciences Journal, 6, no. 3 (2024),
https://doi.org/10.3892/wasj.2024.242 . .

TY  - JOUR
AU  - Mısır, Sema
AU  - Yaman, Serap Özer
AU  - Petrović, Nina
AU  - Sumer, Ceren
AU  - Hepokur, Ceylan
AU  - Aliyazicioglu, Yüksel
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10630
AB  - Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends. Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicin-induced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the identification of new therapeutic targets for the prevention of BC chemoresistance. © 2022, Tech Science Press. All rights reserved.
T2  - Oncology Research
T1  - circRNAs in drug resistance of breast cancer
VL  - 30
IS  - 4
SP  - 157
EP  - 172
DO  - 10.32604/or.2022.027547
ER  - 

@article{
author = "Mısır, Sema and Yaman, Serap Özer and Petrović, Nina and Sumer, Ceren and Hepokur, Ceylan and Aliyazicioglu, Yüksel",
year = "2022",
abstract = "Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends. Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicin-induced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the identification of new therapeutic targets for the prevention of BC chemoresistance. © 2022, Tech Science Press. All rights reserved.",
journal = "Oncology Research",
title = "circRNAs in drug resistance of breast cancer",
volume = "30",
number = "4",
pages = "157-172",
doi = "10.32604/or.2022.027547"
}

Mısır, S., Yaman, S. Ö., Petrović, N., Sumer, C., Hepokur, C.,& Aliyazicioglu, Y.. (2022). circRNAs in drug resistance of breast cancer. in Oncology Research, 30(4), 157-172.
https://doi.org/10.32604/or.2022.027547

Mısır S, Yaman SÖ, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. circRNAs in drug resistance of breast cancer. in Oncology Research. 2022;30(4):157-172.
doi:10.32604/or.2022.027547 .

Mısır, Sema, Yaman, Serap Özer, Petrović, Nina, Sumer, Ceren, Hepokur, Ceylan, Aliyazicioglu, Yüksel, "circRNAs in drug resistance of breast cancer" in Oncology Research, 30, no. 4 (2022):157-172,
https://doi.org/10.32604/or.2022.027547 . .